Table 1.
Characteristics of Study Participants
| Characteristics | EHI ART− (n = 42) | EHI ART+ (n = 11) | CHI ART− (n = 22) | CHI ART+ (n = 71) | UCs (n = 42) |
|---|---|---|---|---|---|
| Age, y | |||||
| Median (IQR) | 34 (31–42) | 40 (29–45) | 38 (33–50) | 55 (50–61) | 52 (46–59) |
| Range | 21–53 | 22–58 | 22–56 | 26–75 | 23–76 |
| Sex, no. (%) | |||||
| Male | 55 (98.2) | 11 (100) | 17 (77.3) | 64 (90.1) | 31 (73.8) |
| Female | 1 (1.8) | 0 (0) | 5 (22.7) | 7 (9.9) | 11 (26.2) |
| CD4 T cells/µL | |||||
| Median (IQR) | 480 (260–670) | 530 (430–660) | 220 (35–345) | 546 (408–700) | 821 (519–1022) |
| Range | 210–910 | 369–912 | 3–489 | 161–1083 | 281–1173 |
| CD8 T cells/µL | |||||
| Median (IQR) | 750 (640–1120) | 590 (392–820) | 770 (406–1147) | 734 (557–997) | 373 (273–535) |
| Range | 300–1460 | 268–1325 | 54–1425 | 300–1213 | 188–843 |
| CD4:CD8 | |||||
| Median (IQR) | 0.6 (0.4–0.8) | 0.8 (0.6–1.4) | 0.2 (0.1–0.4) | 0.7 (0.5–1.0) | 2.1 (1.2–3.0) |
| Range | 0.2–1.2 | 0.5–1.9 | 0.1–1.0 | 0.4–1.2 | 0.4–4.0 |
| VL, log10 copies/mL | |||||
| Median (IQR) | 4.5 (4.2–5.1) | <1.7 | 5.1 (4.4–5.5) | <1.7 | NA |
| Range | 2.8–5.5 | NA | 3.9–5.5 | NA | NA |
N = 146 people living with HIV and 42 UCs.
Abbreviations: ART, antiretroviral therapy; ART−, antiretroviral therapy naive; ART+, on antiretroviral therapy; CHI, chronic HIV infection; EHI, early HIV infection; HIV, human immunodeficiency virus; IQR, interquartile range; NA, not applicable; UC, uninfected control; VL, viral load.